Literature DB >> 9365044

Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism.

M Kin1, M Sata, T Ueno, T Torimura, S Inuzuka, R Tsuji, K Sujaku, M Sakamoto, H Sugawara, S Tamaki, K Tanikawa.   

Abstract

BACKGROUND/AIMS: Basic fibroblast growth factor has mitogenic and angiogenic properties. In this study, we aimed to evaluate the role of fibroblast growth factor in the development and progression of human hepatocellular carcinoma.
METHODS: The expression of basic fibroblast growth factor, fibroblast growth factor receptor-1, and a receptor isoform was investigated by in situ hybridization, immunohistochemistry, reverse transcription-polymerase chain reaction, Western blot analysis and confocal laser-scanning microscopy. The influence of exogenous basic fibroblast growth factor on DNA synthesis and motility of human hepatoma cells were also evaluated.
RESULTS: Basic fibroblast growth factor and fibroblast growth factor receptor-1 messenger RNAs were present mainly in tumor cells and less so in hepatocytes from noncancerous liver tissue. Immunoreactive products of basic fibroblast growth factor and fibroblast growth factor receptor-1 were observed in tumor cells. The isoform IIIc was expressed in hepatocellular carcinoma tissue and hepatoma cell lines. Exogenous basic fibroblast growth factor stimulated DNA synthesis and motility of hepatoma cells. The effect was more marked in poorly-differentiated hepatoma cells than in well-differentiated hepatoma cells. Fibroblast growth factor-1 expression on hepatoma cells was also more marked in poorly-differentiated hepatoma cells than in well-differentiated hepatoma cells. The stimulated motility on basic fibroblast growth factor was suppressed by an anti-fibroblast growth factor receptor-1 antibody.
CONCLUSIONS: Basic fibroblast growth factor may play an important role in the development and progression of hepatocellular carcinoma via an autocrine mechanism involving fibroblast growth factor and its receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9365044     DOI: 10.1016/s0168-8278(97)80085-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  15 in total

Review 1.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

2.  mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma.

Authors:  Kimberly J Riehle; Matthew M Yeh; Jeannette J Yu; Heidi L Kenerson; William P Harris; James O Park; Raymond S Yeung
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

3.  A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts.

Authors:  Lihong Wang; Hangil Park; Sophea Chhim; Yi Ding; Wei Jiang; Cary Queen; K Jin Kim
Journal:  Mol Cancer Ther       Date:  2012-02-16       Impact factor: 6.261

Review 4.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

5.  Association of Genetic Polymorphisms With Hepatitis C Virus-related Liver Cirrhosis in Japan.

Authors:  Shinya Kamimura; Akinori Tamura; Tomotaka Ishii; Tatsuo Kanda; Mitsuhiko Moriyama
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 6.  Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives.

Authors:  Hui-Chuan Sun; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-18       Impact factor: 4.553

7.  Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis.

Authors:  Xinqiang Huang; Chaofeng Yang; Chengliu Jin; Yongde Luo; Fen Wang; Wallace L McKeehan
Journal:  Mol Carcinog       Date:  2009-06       Impact factor: 4.784

8.  Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.

Authors:  Mahmoud Ma Elsayed; Mahmoud E Mostafa; Eman Alaaeldin; Hatem Aa Sarhan; Montaser ShA Shaykoon; Shady Allam; Ahmed Rh Ahmed; Bakheet Em Elsadek
Journal:  Int J Nanomedicine       Date:  2019-10-29

Review 9.  Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies.

Authors:  Mohamed R Akl; Poonam Nagpal; Nehad M Ayoub; Betty Tai; Sathyen A Prabhu; Catherine M Capac; Matthew Gliksman; Andre Goy; K Stephen Suh
Journal:  Oncotarget       Date:  2016-07-12

10.  Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells.

Authors:  Wang Chengye; Tian Yu; Shao Ping; Sun Deguang; Wang Keyun; Wang Yan; Zhang Rixin; Liang Rui; Gao Zhenming; Ye Mingliang; Wang Liming
Journal:  Oncotarget       Date:  2017-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.